Impact of a Hospital Pharmacist's Intervention on FENO (Fractional Exhaled Nitric Oxide) in Asthmatic Patients
NCT ID: NCT03093363
Last Updated: 2017-10-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
68 participants
INTERVENTIONAL
2016-10-31
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Asthmatic patients with the pharmacist's intervention
Pharmacist's intervention
Pharmacist's intervention with asthmatic patients:
* Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
* Explanation of asthma and inflammation
* Explanation of triggers and how to avoid it
* Explanation of asthma treatments
* Explanation of the inhalation technique with a physical demonstration
* Emphasis on treatment adherence
* Assessment of comorbidities and their treatment
* Emphasis on influenza vaccination
Control group
Asthmatic patients without the pharmacist's intervention (only questionnaires)
Questionnaires for control group
\- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmacist's intervention
Pharmacist's intervention with asthmatic patients:
* Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
* Explanation of asthma and inflammation
* Explanation of triggers and how to avoid it
* Explanation of asthma treatments
* Explanation of the inhalation technique with a physical demonstration
* Emphasis on treatment adherence
* Assessment of comorbidities and their treatment
* Emphasis on influenza vaccination
Questionnaires for control group
\- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* unchanged or increased dose of inhaled corticosteroids prescribed by the pneumologist at the visit
* FENO (fractional exhaled nitric oxide) \> or = 25 ppb
Exclusion Criteria
* Change of the dose of ICS (inhaled corticosteroids) during the follow-up of 3 months after the pharmacist's intervention
* Severe asthma exacerbation requiring oral corticosteroids within the 4 weeks before the follow-up visit (3 months after the pharmacist's intervention)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Liege
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Renaud Louis
Professor, MD, PhD
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B707201629850
Identifier Type: -
Identifier Source: org_study_id